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refluxed at 50 °C. After 2 days, the solvent was evaporated and the residue was suspended with water (30 mL). The product was extracted with CH 2 Cl 2 and dried over MgSO 4 . After solvent evaporation, the product was purified by column chromatography (CH 2 Cl 2 :methanol, 15:1 v/v) to yield compound 3 as a yellow oil (0.9 g, 90% yield).
1 H NMR (400 MHz, CDCl 3 ): δ 1.02 (s, 3H), 1.34-1.44 (m, 5H), 2.23 (t, 1H, J = 2.4 Hz), 2.64-2.68 (m, 2H), 3.40 (d, 2H, J = 2.4 Hz). 13 C NMR (400 MHz, CDCl 3 ): δ 19. 6, 24.1, 25.5, 31.9, 37.9, 47.7, 71.2, 81.9. 4. Synthesis of (4aR,5R,6aS,6bR,10S,12aR)-5,10-dihydroxy-2,2,6a,6b,9,9,12a -heptamethyl-N-(3-(3-methyl-3H-diazirin-3-yl)propyl)-N-(prop-2-yn-1-yl)-1, 3,4,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-octadecahydropicene-4a(2H)-carboxamide (4) .
N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC, 50 mg, 0.25 mmol) was added to echinocystic acid (EA, 80 mg, 0.17 mmol) in 6 mL of dry tetrahydrofuran (THF) with stirring. After 0.5 h, compound 3 (30.2 mg, 0.2 mmol) was added to the mixture. The mixture was stirred at RT until completion, as determined by TLC. The solvent was evaporated, the residue was suspended in EtOAc (30 mL), washed with water (20 mL × 3) and saline, dried over Na 2 SO 4 , filtered, and concentrated. The crude product was purified by column chromatography (petroleum ether:EtOAc, 3:1 v/v) to yield compound 4 as a white solid (78 mg, 76% yield (brs, 1H).
13
C NMR (100 MHz, CDCl 3 ): δ 15. 5, 15.5, 17.0, 18.2, 19.7, 21.8, 23.3, 25.4, 26.4, 27.1, 28.0, 28.1, 29.3, 31.7, 32.6, 33.0, 34.7, 36.4, 37.0, 38.2, 38.5, 38.7, 39.8, 41.6, 42.7, 46.7, 46.9, 48.0, 50.4, 55.3, 72.2, 72.2, 78.8, 79.2, 122.8, 142.6, 175.5 5. Synthesis of (4aR,6aS,6bR,12aR)-2,2,6a,6b,9,9,12a-heptamethyl-N-(3 -(3-methyl-3H- 3,4,5,6,6a, 6b,7,8,8a,9,10,11,12,12a,12b,13,14b-octadecahydropicene-4a (2H)-carboxamide (Y18).
Dess-Maritin periodinane (212 mg, 0.5 mmol) was added to a solution of compound 4 (60 mg, 0.1 mmol) in 8 mL of CH 2 Cl 2 . The reaction was stirred at RT for 30 min after completion (TLC), and then excess saturated aqueous Na 2 S 2 O 3 was added to the reaction mixture. The mixture was extracted with CH 2 Cl 2 (3 × 10 mL). The combined organic layers were washed with saturated aqueous NaHCO 3 , dried over Na 2 SO 4 , filtered, and concentrated. 31, 213.87, 170.19, 141.04, 123.34, 77.20, 73.09, 60.12, 55.18, 50.06, 49.25, 47.32, 46.74, 46.61, 46.13, 45.69, 39.71, 39.00, 36.78, 36.67, 34.24, 34.02, 32.48, 31.75, 30.42, 26.53, 26.19, 26.10, 25.41, 23.69, 23.48, 22.56, 21.42, 19.76, 19.48, 17.09, 15.07 
Synthesis of Biotin-azide.
(a) N-Hydroxysuccinimide, EDC, DMF, RT; (b) 2-azidoethylamine, TEA, DMF, RT.
1. Synthesis of 2,5-dioxopyrrolidin-1-yl 5-((3aS, 4S, 6aR)-2-oxohexahydro-1H -thieno [3,4-d] imidazole-4-yl)pentanoate (1).
To D-biotin (488 mg, 2 mmol) stirring in 8 mL DMF, N-hydroxysuccinimide (344 mg, 3 mmol) and EDC (576 mg, 3 mmol) were added. The mixture was stirred at rt overnight. The reaction mixture was then poured into ice (400 mL), and the precipitate was filtered. The precipitate was washed twice and dried under reduced pressure to afford 1 as a white solid (580 mg, 85%).
2. Synthesis of N-(2-azidoethyl)-5-((3aS, 4S, 6aR)-2-oxohexahydro-1H -thieno [3,4-d] imidazole-4-yl)pentanoate (Biotin-azide).
To compound 1 (96mg, 0.28 mmol) stirring in 3 mL DMF, TEA (80 µL, 0.70 mmol) and 2-azidoethylamine (48 mg, 0.56 mmol) were added. The reaction was stirred for 6 h at rt. The contents were evaporated under reduced pressure. 01, 176.44, 61.02, 59.19, 55.38, 49.98, 38.13, 35.12, 28.17, 25.13 .
Synthesis of Y0.
(a) Benzyl bromide, K 2 CO 3, DMF, 60 °C, 24 h; (b) PCC, CH 2 Cl 2 , RT, overnight; (c) H 2 , Pd/C, THF/MeOH, RT, overnight.
1. Synthesis of benzyl(4aR,5R,6aS,6bR,10S,12aR)-5,10-dihydroxy-2, 2,6a,6b, 9,9,12a-heptamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-octadecahydropicene-4a 51, 142.63, 136.08, 128.46, 128.07, 128.05, 123.01, 78.97, 75.00, 66.33, 55.30, 48.84, 46.74, 46.38, 41.36, 40.74, 39.53, 38.76, 38.54, 37.02, 35.54, 35.46, 32.94, 32.77, 30.58, 30.39, 28.09, 27.23, 27.01, 24.70, 23.31, 18.29, 17.00, 15.59, 15.46. 2. Synthesis of benzyl (4aR, 6aS, 6bR, 2, 6a, 6b, 9, 9, 3, 4, 5, 6, 6a, 6b, 7, 8, 8a, 9, 10, 11, 12, 12a, 12b, 13, 208.17, 172.36, 140.27, 135.16, 128.44, 128.31, 128.28, 124.04, 66.80, 58.87, 55.04, 47.66, 47.22, 46.38, 46.15, 45.58, 45.16, 39.48, 38.89, 36.50, 34.38, 33.91, 32.66, 31.98, 30.45, 27.01, 26.61, 26.42, 23.38, 23.16, 21.35, 19.32, 16.62, 14.88 3. Synthesis of (6aR,6bS,14bR)-4,4,6a,6b,11,11,14b-heptamethyl-1,4a,5,6,6a,6b,7,8a, 9,10,11,12,12a,14,14a,14b-hexadecahydropicene-3,8(2H,4H) 
Compound 2 (200 mg, 0.36 mmol) was dissolved in THF/MeOH (1:1 v/v, 12 mL) and 10%
palladium-carbon (20 mg) was added. The reaction mixture was stirred under hydrogen gas (0.35 MPa) overnight. After removing the catalyst by filtration with the aid of celite, the filtrate was concentrated and then purified by column chromatography over silica gel to afford compound Y0 as a white solid (125 mg, 82% yield 24, 214.20, 142.61, 122.33, 55.20, 47.52, 27.33, 47.11, 46.73, 46.48, 46.04, 44.73, 39.44, 38.98, 36.76, 34.33, 34.01, 33.24, 32.25, 30.89, 26.72, 26.55, 23.39, 21.41, 20.84, 19.51, 17.37, 15 
Synthesis of probe Y20.
(a) liquid ammonia, NH 2 OSO 3 H, I 2 , methanol, trimethylamine, RT, 5 h; (b) TsCl, pyridine, overnight; (c) methyl glycinate, KI, K 2 CO 3 , CH 3 CN, 70 °C, overnight; (d) methyl 8-amino-octanoate, Na 2 CO 3 , DMF, overnight; (e) NaOH (1 N), THF, methanol, RT, 3 h; (f) EDC, THF, 50 °C, RT, refluxed; (g) NaOH (1 N), THF, methanol, RT, 3 h.
1. Synthesis of 3-(3-methyl-3H-diazirin-3-yl)propan-1-ol (1).
5-hydroxy-2-pentanone (10 g, 0.1 mol) was added to 40 mL of NH 3 and stirred for 3 h at -78 °C.
Hydroxylamine-O-sulfonic acid (15 g, 0.13 mol) was dissolved in methanol and poured into the reaction mixture. After stirring overnight, the white precipitate was filtered and methanol was added to the ice-cold reaction mixture, followed by triethylamine. Iodine was slowly added until the iodine colour persisted. After 2 h, the methanol was evaporated and the reaction mixture was extracted with ether and dried over MgSO 4 . Vacuum distillation was performed to obtain the final pale yellow oil 1 (4.5 g, 40.3% overall yield).
2. Synthesis of 3-(3-methyl-3H-diazirin-3-yl)propyl 4-methylbenzenesulfonate (2).
Three millilitres of triethylamine was added to a solution of compound 1 (1.14 g, 10 mmol) in 40 mL of CH 2 Cl 2 at 0 °C, followed by the step-wise addition of p-toluenesulfonyl chloride (2.86 g, 15 mmol). The reaction mixture was stirred at room temperature (RT) overnight. After completion, as determined by TLC, the reaction mixture was treated with 1 N HCl. The organic phase was separated and the aqueous phase was extracted with CH 2 Cl 2 . The combined extracts were washed with 1 N HCl and 1 N NaOH, dried over Na 2 SO 4 , filtered, and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether : EtOAc, 10:1 v/v) to yield compound 2 as a viscous oil (2.2 g, 82% yield BA·OBT (166 mg, 0.28 mmol) was dissolved in 10 mL of DMF and then added to methyl 8-aminooctanoate (173 mg, 0.56 mmol) and NaCO 3 (100 mg, 0.94 mmol). The reaction mixture was subjected to stirring overnight. Subsequently, the reaction mixture was evaporated under a vacuum to remove the DMF; 50 mL saline was then added, and the water layer was washed with EtOAc three times, dried with Na 2 SO 4 , filtered and concentrated. The residue was purified by silica gel column chromatography to afford compound 4 as a white solid with a 41% yield. Compound 4 (160 mg, 0.26 mmol) was dissolved in THF (16 mL) and MeOH (4 mL); then, an aqueous 1 N NaOH solution (1.6 mL) was added to the resulting solution at 0 °C. The reaction mixture was stirred at room temperature for 3 h, vacuum-evaporated to remove the solvent and incubated in with an aqueous 1 N HCl solution in an ice bath to reach a pH value of 2-3. 55.58, 55.36, 50.60, 50.10, 46.73, 42.45, 40.72, 39.13, 38.80, 38.69, 38.45, 37.71, 37.16, 34.38, 33.93, 33.84, 30.86, 29.72, 29.40, 28.93, 28.83, 27.94, 27.29, 26.72, 25.60, 24.55, 20.90, 19.47, 18.25, 16.11, 16.10, 15.33, 14.61. 6. Synthesis of methyl N-(8-((1R,3aS,5aR,5bR,9S,11aR)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-
Compound 3 (15.5 mg, 0.08 mmol) and compound 5 (50 mg, 0.08 mmol) were dissolved in 15 mL of THF and then EDC was added (14 mg, 0.13 mmol). The reaction mixture was refluxed at 50 °C for 12 h and then vacuum-evaporated to remove the solvent. The residue was purified by silica gel column chromatography (elute: petroleum ether:ethyl acetate = 2:1) to afford compound 6 as a white solid with a 52% yield. R f = 0. 173.33, 169.86, 151.03, 109.23, 78.92, 77.32, 77.00, 76.68, 55.54, 55.36, 52.05, 50.61, 50.12, 48.32, 47.55, 46.74, 42.44, 40.72, 39.11, 38.82, 38.69, 38.43, 37.69, 37.17, 34.38, 33.82, 32.55, 31.53, 31.06, 30.87, 29.72, 29.39, 29.20, 29.02, 27.95, 27.39, 26.76, 25.60, 25.19, 24.93, 23.16, 20.90, 19.93, 19.46, 18.27, 16.11, 15.33, 14. 
Compound 6 (12 mg, 0.016 mmol) was dissolved in 4:1 THF:MeOH; then, an aqueous 1 N NaOH solution (100 μL) was added to the resulting solution at 0 °C. The reaction mixture was stirred at room temperature and reacted for 3 h, vacuum-evaporated to remove the solvent, and incubated with an aqueous 1 N HCl solution to reach a pH value of 2-3. The precipitate was collected and vacuum-dried to obtain Y20 as a white solid, with a yield of 70%. 46.73, 42.44, 40.71, 39.21, 38.79, 38.67, 38.47, 37.70, 37.14, 34.35, 33.76, 32.55, 31.58, 31.03, 30.84, 29.60, 29.38, 29.06, 28.87, 27.94, 27.26, 26.70, 25.58, 25.20, 24.96, 23.10, 20.89, 19.90, 19.44, 18.26, 16.12, 15.36, 14.61 1. Synthesis of 3-methyl-3H-diazirine-3-propanoic acid (1).
A solution of levulinic acid (500 mg, 4.3 mmol) in MeOH (2.0 mL) was cooled in an ice bath. To this solution was added 7 N ammonia (5.0 mL in MeOH) via syringe. The mixture was allowed to stir for 3 h at 0 °C at which point a solution of hydroxylamine-O-sulfonic acid (729 mg, 6.5 mmol) in MeOH (5 mL) was added. The reaction mixture was stirred for 16 h while the icewater bath was allowed to warm to 25 °C. The excess ammonia was removed by gently blowing air through the suspension for 1 h using a glass pipette. The suspension was filtered and the filtrate concentrated by rotary evaporation. The solid mass was dissolved MeOH (20 mL) and cooled in an ice bath. Triethylamine (1.1 mL, 7.9 mmol) was added and the solution was allowed to stir for 5 minutes. Iodine was added until the color remained. The solution was diluted with EtOAc (30 mL) and successively washed with 1 N HCl (20 mL), a 10% sodium thiosulfate solution (20 mL), saturated aqueous NaCl (20 mL), and finally dried over anhydrous Na 2 SO 4 .
The organic solvents were removed by rotary evaporation to afford yellow oil 1 (375 mg, 68% 2. Synthesis of 3-methyl-3H-diazirine-3-propanoyl chloride (2).
Oxalyl chloride (471 μL, 5.6 mmol) and DMF (4 drops) were added to a solution of 1 (178 mg, 1.4 mmol) in 12 mL of redistilled DCM at 0℃. The reaction mixture was stirred at room temperature (RT) overnight. After completion, the solvents were removed by rotary evaporation to give 2 without further purification.
Synthesis of β-D-galactopyranosyl azide (3).
To a stirring solution of 2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl azide (1.7 g, 4.6 mmol) in dry MeOH (30 mL) was added a solution of sodium methoxide (1M in MeOH) until pH 9-10 (250 μL). The reaction mixture was stirred at r.t. for 3 h. The solution was then neutralized by addition of ionexchange resin (Dowex 50WX4) until pH 7, filtered, and the solvent was removed under reduced pressure. The residue was then purified by column chromatography (CH 2 Cl 2 :CH 3 OH, 8:1 v/v) to give 3 as a white solid (820 mg, 4.0 mmol, 87% yield).
Synthesis of 6-O-(3-methyl-3H-diazirine-3-propionyl)-β-D-galactopyranosyl azide (4).
To a stirring solution of 3 (212 mg, 1.03 mmol) in DMF/THF (20/15 mL) was added a solution of 2 (~1.2 mmol) in DCM (8 mL) and TEA (428 μL, 3.09 mmol) at 0 °C. The reaction mixture was stirred at RT overnight. After completion, as determined by TLC, the reaction mixture was concentrated under reduced pressure. To a solution of 4 (100 mg, 0.32 mmol) in anhydrous pyridine (5 mL) at 0 °C acetic anhydride (0.44 mL) was added, and the solution was stirred overnight at RT. The solution was moved under reduced pressure and then diluted with dichloromethane, and the organic phase was dried with Na 2 SO 4 . The residue was then purified by column chromatography (petroleum ether:EtOAc, 4:1 v/v) to give 5 as the colorless oil (136 mg, 0.31 mmol, 97% yield 57, 169.99, 169.82, 169.24, 88.20, 72.71, 70.63, 68.03, 66.82, 61.38, 29.42, 28.48, 24.99, 20.54, 20.48, 20.39, 19.46 7. Synthesis of (4aR, 5R, 6aS, 6bR, 10S, 12aR)-10-hydroxy-2,2,6a,6b,9,9,12a -heptamethyl- 3,4,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-octadecahydropicene-4a 92, 171.59, 171.07, 169.95, 169.71, 143.70, 123.46, 78.88, 78.61, 71.69, 70.74, 68.27, 67.06, 60.93, 55.12, 47.51, 46.57, 46.42, 41.97, 41.29, 39.34, 38.72, 38.51, 36.92, 34.13, 32.83, 32.51, 30.58, 29.45, 28.48, 28.04, 27.21, 27.13, 25.47, 24.99, 24.06, 23.52, 23.19, 20.74, 20.52, 20.50, 19.50, 18.27, 17.06 
Synthesis of compounds Y1-Y4, Y9-Y16 and Y19.
The synthesis procedures and characterization of compounds Y1-Y4 and Y9-Y16 have been reported in our previous study(7). And the synthesis procedure and characterization of compound Y19 have been reported by other group(24). The time-of-addition experimental scheme. In the first assay, the entry experiment, the host cells were infected with viruses in the presence of a compound at 37 °C for 1 h, then washed to remove the unbound viruses and compound and cultured at 37 °C for 72 h. In the second assay, the attachment experiment, cells were inoculated with EBOVpp in the presence of the lead compound at 4 °C for 1 h, allowing virus attachment but not membrane fusion due to the energy requirement, then washed to remove the unbound viruses and lead compounds and continuously cultured at 37 °C for 72 h. In the third assay, the fusion experiment, cells were first incubated with EBOVpp at 4 °C for 1 h to allow viral attachment, washed to remove any unbound virus, and then treated with the lead compound at 37 °C for 1 h to allow virus fusion.
After being washed to remove the unbound lead compound, infected cells were continuously cultured at 37 °C for 72 h. In the fourth assay, post-entry experiment, cells were first treated with EBOVpp at 37 °C for 1 h to allow the virus entry into the cells. After being washed to remove the unbound viruses, the infected cells were treated with the lead compound at 37 °C for 72 h. In the fifth assay, pretreatment of cells, cells were incubated with the lead compound at 4 °C for 1 h and then washed to remove the unbound compounds. The pretreated cells were exposed to EBOVpp for 1 h, then washed to remove unbound viruses and cultured at 37 °C for 72 h. In the sixth assay, pretreatment of the viruses, EBOVpp was incubated with the lead compound at 4 °C for 30 minutes and then washed to remove the unbound compounds by ultrafiltration. The host cells were inoculated with the pretreated viruses for 1 h, then washed to remove unbound viruses and cultured at 37 °C for 72 h. The luciferase activity was tested to reflect the viral infectivity.
(B) The inhibition rates of the lead compounds toward viral infection under different conditions.
E-64d was used as a control. Data are presented as the mean ± s.d. (n = 3). study. According to our study, although triterpenoids contain the alike pentacyclic scaffolds, many small differences appear in the structures of different types of triterpenoids, leading to their specific inhibition of different viruses: EA and its derivatives tend to specifically inhibit HCV fusion; OA and its derivatives tend to specifically inhibit influenza virus fusion; BA and its derivatives tend to specifically inhibit HIV fusion; the oxidation products of EA and OA and their derivatives tend to specifically inhibit EBOV and MARV fusion; and ursolic acid and its derivatives tend to specifically inhibit VSV fusion. Table S1 . Broad antiviral spectra of the tested compounds against various EBOV subtypes and MARV.
